© 2017 Springer Science+Business Media B.V. Clinical use of boric acid as a topical antifungal in women who have failed standard antifungal therapy with azole drugs has been used sporadically for decades. Our previous in vitro work showing inhibition of Candida albicans growth was conducted on clinical isolates without antifungal drug susceptibility profiling. Here, we report that boric acid restricts growth of drug-resistant Candida albicans and inhibits hyphal growth and diminishes cell volume. The availability of over-the-counter organoboron compounds intended for use as oral nutritional supplements led us to determine if these also were inhibitory toward resistant Candida and show here that they also possess antifungal activity. Candida glabrata was also found to be inhibited by boric acid and organoboron compounds. Further development of organoboron compounds as topical therapeutics is of potential value.
- Boric acid
- Candida albicans
- Candida glabrata
- Drug resistant
Larsen, B., Petrovic, M., & DeSeta, F. (Accepted/In press). Boric Acid and Commercial Organoboron Products as Inhibitors of Drug-Resistant Candida albicans. Mycopathologia, 1-9. https://doi.org/10.1007/s11046-017-0209-6